{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:46:49Z","timestamp":1790336809456,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA264102-01"],"award-info":[{"award-number":["1R01CA264102-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41565-021-01032-w","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T12:05:43Z","timestamp":1639656343000},"page":"206-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5758","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Kucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Soker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl W.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-0040","authenticated-orcid":false,"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina R.","family":"Bellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amyn A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Jeffrey","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-1698","authenticated-orcid":false,"given":"Dawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"1032_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","volume":"15","author":"MM Zamboni","year":"2015","unstructured":"Zamboni, M. M., da Silva, C. T. Jr., Baretta, R., Cunha, E. T. & Cardoso, G. P. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm. Med. 15, 29 (2015).","journal-title":"BMC Pulm. Med."},{"key":"1032_CR2","doi-asserted-by":"publisher","first-page":"e1554969","DOI":"10.1080\/2162402X.2018.1554969","volume":"8","author":"P Murthy","year":"2019","unstructured":"Murthy, P. et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology 8, e1554969 (2019).","journal-title":"Oncoimmunology"},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","volume":"7","author":"D Morgensztern","year":"2012","unstructured":"Morgensztern, D., Waqar, S., Subramanian, J., Trinkaus, K. & Govindan, R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J. Thorac. Oncol. 7, 1485\u20131489 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"1032_CR4","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Management of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 162, 1987\u20132001 (2000).","DOI":"10.1164\/ajrccm.162.5.ats8-00"},{"key":"1032_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","volume":"186","author":"GT Stathopoulos","year":"2012","unstructured":"Stathopoulos, G. T. & Kalomenidis, I. Malignant pleural effusion: tumor-host interactions unleashed. Am. J. Respir. Crit. Care Med. 186, 487\u2013492 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1032_CR6","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","volume":"11","author":"LA Lievense","year":"2016","unstructured":"Lievense, L. A. et al. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression. J. Thorac. Oncol. 11, 1755\u20131764 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"1032_CR7","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.18632\/oncotarget.27290","volume":"10","author":"AD Donnenberg","year":"2019","unstructured":"Donnenberg, A. D., Luketich, J. D. & Donnenberg, V. S. Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications. Oncotarget 10, 6456\u20136465 (2019).","journal-title":"Oncotarget"},{"key":"1032_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","volume":"193","author":"R Cornelissen","year":"2016","unstructured":"Cornelissen, R. et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 193, 1023\u20131031 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1032_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/crj.13010","volume":"13","author":"V Murthy","year":"2019","unstructured":"Murthy, V., Katzman, D. & Sterman, D. H. Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy. Clin. Respir. J. 13, 272\u2013279 (2019).","journal-title":"Clin. Respir. J."},{"key":"1032_CR10","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","volume":"11","author":"S Khanna","year":"2016","unstructured":"Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993\u20132005 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"1032_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jtho.2017.10.034","volume":"13","author":"YH Tseng","year":"2018","unstructured":"Tseng, Y. H. et al. PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion. J. Thorac. Oncol. 13, 447\u2013453 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1032_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62813-2","volume":"10","author":"B Ghanim","year":"2020","unstructured":"Ghanim, B. et al. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Sci. Rep. 10, 5784 (2020).","journal-title":"Sci. Rep."},{"key":"1032_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","volume":"5","author":"R Hassan","year":"2019","unstructured":"Hassan, R. et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 5, 351\u2013357 (2019).","journal-title":"JAMA Oncol."},{"key":"1032_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.21037\/tlcr.2017.04.01","volume":"6","author":"EW Alley","year":"2017","unstructured":"Alley, E. W., Katz, S. I., Cengel, K. A. & Simone, C. B. II Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl. Lung Cancer Res. 6, 212\u2013219 (2017).","journal-title":"Transl. Lung Cancer Res."},{"key":"1032_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF00199131","volume":"22","author":"W Bakker","year":"1986","unstructured":"Bakker, W., Nijhuis-Heddes, J. M. & van der Velde, E. A. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol. Immunother. 22, 155\u2013159 (1986).","journal-title":"Cancer Immunol. Immunother."},{"key":"1032_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s002620050407","volume":"45","author":"H Yanagawa","year":"1997","unstructured":"Yanagawa, H. et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol. Immunother. 45, 93\u201399 (1997).","journal-title":"Cancer Immunol. Immunother."},{"key":"1032_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.2004.09.164","volume":"22","author":"S Sartori","year":"2004","unstructured":"Sartori, S. et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J. Clin. Oncol. 22, 1228\u20131233 (2004).","journal-title":"J. Clin. Oncol."},{"key":"1032_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/bjc.1995.501","volume":"72","author":"SH Goey","year":"1995","unstructured":"Goey, S. H. et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I\u2013II study. Br. J. Cancer 72, 1283\u20131288 (1995).","journal-title":"Br. J. Cancer"},{"key":"1032_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","volume":"7","author":"AD Donnenberg","year":"2019","unstructured":"Donnenberg, A. D., Luketich, J. D., Dhupar, R. & Donnenberg, V. S. Treatment of malignant pleural effusions: the case for localized immunotherapy. J. Immunother. Cancer 7, 110 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1032_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","volume":"15","author":"GN Barber","year":"2015","unstructured":"Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760\u2013770 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1032_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"1032_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786\u2013791 (2013).","journal-title":"Science"},{"key":"1032_CR23","first-page":"843","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor. Immun. Immunogenic Tumors Immun. 41, 843\u2013852 (2014).","journal-title":"Immun. Immunogenic Tumors Immun."},{"key":"1032_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","volume":"76","author":"JR Baird","year":"2016","unstructured":"Baird, J. R. et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 76, 50\u201361 (2016).","journal-title":"Cancer Res."},{"key":"1032_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269\u2013278 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"1032_CR26","doi-asserted-by":"publisher","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","volume":"10","author":"CG Park","year":"2018","unstructured":"Park, C. G. et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1032_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nchembio.1661","volume":"10","author":"L Li","year":"2014","unstructured":"Li, L. et al. Hydrolysis of 2'3\u2019-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043\u20131048 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"1032_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06922-7","volume":"9","author":"K Kato","year":"2018","unstructured":"Kato, K. et al. Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1. Nat. Commun. 9, 4424 (2018).","journal-title":"Nat. Commun."},{"key":"1032_CR29","doi-asserted-by":"crossref","unstructured":"Onyedibe, K. I., Wang, M. & Sintim, H. O. ENPP1, an old enzyme with new functions, and small molecule inhibitors-A STING in the tale of ENPP1. Molecules 24 (2019).","DOI":"10.3390\/molecules24224192"},{"key":"1032_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1432-1033.1993.tb18261.x","volume":"217","author":"SI Belli","year":"1993","unstructured":"Belli, S. I., van Driel, I. R. & Goding, J. W. Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5\u2019-nucleotide phosphodiesterase). Eur. J. Biochem. 217, 421\u2013428 (1993).","journal-title":"Eur. J. Biochem."},{"key":"1032_CR31","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"1032_CR32","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med."},{"key":"1032_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00573-w","volume":"8","author":"MF Gulen","year":"2017","unstructured":"Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).","journal-title":"Nat. Commun."},{"key":"1032_CR34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1084\/jem.20161674","volume":"214","author":"S Cerboni","year":"2017","unstructured":"Cerboni, S. et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J. Exp. Med. 214, 1769\u20131785 (2017).","journal-title":"J. Exp. Med."},{"key":"1032_CR35","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1172\/JCI127458","volume":"129","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. J. Clin. Invest. 129, 4224\u20134238 (2019).","journal-title":"J. Clin. Invest."},{"key":"1032_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 938 (2014).","journal-title":"Cancer Cell"},{"key":"1032_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13720","volume":"7","author":"D Laoui","year":"2016","unstructured":"Laoui, D. et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun. 7, 13720 (2016).","journal-title":"Nat. Commun."},{"key":"1032_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"1032_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"1032_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"1032_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.immuni.2014.07.003","volume":"41","author":"L Gattinoni","year":"2014","unstructured":"Gattinoni, L. Memory T cells officially join the stem cell club. Immunity 41, 7\u20139 (2014).","journal-title":"Immunity"},{"key":"1032_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609\u2013614 (2020).","journal-title":"Nature"},{"key":"1032_CR43","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"1032_CR44","doi-asserted-by":"publisher","first-page":"2438598","DOI":"10.1155\/2018\/2438598","volume":"2018","author":"A Bosi","year":"2018","unstructured":"Bosi, A. et al. Natural killer cells from malignant pleural effusion are endowed with a decidual-like proangiogenic polarization. J. Immunol. Res. 2018, 2438598 (2018).","journal-title":"J. Immunol. Res."},{"key":"1032_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/eji.201242783","volume":"43","author":"P Vacca","year":"2013","unstructured":"Vacca, P. et al. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur. J. Immunol. 43, 550\u2013561 (2013).","journal-title":"Eur. J. Immunol."},{"key":"1032_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan, R. et al. FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28, 285\u2013295 (2015).","journal-title":"Cancer Cell"},{"key":"1032_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 family revisited. Annu Rev. Immunol. 23, 515\u2013548 (2005).","journal-title":"Annu Rev. Immunol."},{"key":"1032_CR48","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","volume":"181","author":"AL Kinter","year":"2008","unstructured":"Kinter, A. L. et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181, 6738\u20136746 (2008).","journal-title":"J. Immunol."},{"key":"1032_CR49","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Disco. 4, 674\u2013687 (2014).","journal-title":"Cancer Disco."},{"key":"1032_CR50","doi-asserted-by":"crossref","unstructured":"Dhupar, R. et al. Characteristics of malignant pleural effusion resident CD8(+) T cells from a heterogeneous collection of tumors. Int. J. Mol. Sci. 21 (2020).","DOI":"10.3390\/ijms21176178"},{"key":"1032_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","volume":"4","author":"P DeLong","year":"2005","unstructured":"DeLong, P. et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol. Ther. 4, 342\u2013346 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"1032_CR52","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00262-020-02781-8","volume":"70","author":"MF Wu","year":"2021","unstructured":"Wu, M. F. et al. The M1\/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer. Cancer Immunol. Immunother. 70, 1435\u20131450 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1032_CR53","doi-asserted-by":"publisher","first-page":"eaat5690","DOI":"10.1126\/scitranslmed.aat5690","volume":"11","author":"M Guo","year":"2019","unstructured":"Guo, M. et al. Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci. Transl. Med. 11, eaat5690 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1032_CR54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","volume":"158","author":"J Li","year":"2012","unstructured":"Li, J., Yang, Y. & Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 158, 108\u2013114 (2012).","journal-title":"J. Control. Release"},{"key":"1032_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13094-5","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nat. Commun. 10, 5108 (2019).","journal-title":"Nat. Commun."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-021-01032-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-021-01032-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-021-01032-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T08:26:26Z","timestamp":1676017586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-021-01032-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1038\/s41565-021-01032-w","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}